Drug
Ak112 Low Dose
Ak112 Low Dose: highest development phase Phase 1/2, developed by Akeso. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Akeso
Trials
| Drug | Phase | Indication |
|---|---|---|
| AK112 low dose NCT04999605 | Phase 1/2 | Ovarian Neoplasms |
Latest
No recent events.
Follow Ak112 Low Dose on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.